论文信息 - GRPR antagonists for prostate cancer—prospects and caveats - 字舞流文

GRPR antagonists for prostate cancer—prospects and caveats

R. Roesler | G. Schwartsmann

[1] J. Reubi,et al. Targeting GRPR in urological cancers—from basic research to clinical application , 2013, Nature Reviews Urology.

[2] G. Kristiansen,et al. Profiling gastrin‐releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates , 2012, The Prostate.

[3] A. Borowsky,et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. , 2009, Cancer research.

[4] R. Roesler,et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models , 2009, Journal of Neuro-Oncology.

[5] P. Pohlmann,et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies , 2006, Investigational New Drugs.

[6] G. Amorino,et al. Neuroendocrine cells in prostate cancer. , 2004, Critical reviews in eukaryotic gene expression.

[7] A. Lazaris,et al. Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer , 2003, World Journal of Urology.